Needham Reiterates Hold on Neurocrine Biosciences
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Hold rating on Neurocrine Biosciences (NASDAQ:NBIX).
August 01, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Ami Fadia has reiterated a Hold rating on Neurocrine Biosciences (NASDAQ:NBIX). This suggests that the analyst does not see significant upside or downside potential in the near term.
The Hold rating suggests that the analyst believes the stock is fairly valued at its current price. This typically indicates a neutral outlook, with no strong catalysts expected to drive the stock significantly up or down in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100